This FDA Story is an illustrative, anonymized composite created for education. It is not a claim about a named company or a specific FDA enforcement record.
An independent skincare brand sold a vitamin C serum through its own website and two US online marketplaces. In 2024 it registered its contract manufacturer's facility and listed its products with FDA, carefully and on time. Its US labels had been professionally reviewed. By every measure the brand had done MoCRA properly.
A small change to a best-seller
In early 2026 the brand's contract manufacturer recommended a new, more stable vitamin C derivative and a botanical extract to improve the texture. The marketing team liked the result, and the new formula went into production in March. Packaging was reprinted with an updated ingredient list that the in-house designer copied from the manufacturer's specification sheet. Nobody updated the FDA product listing. Nobody asked for a label review. Nobody asked the safety assessor to look at the new formula.
One complaint, three problems
In the summer a customer reported a strong reaction around the eyes after applying the serum. The brand handled the report and assessed it as non-serious. But when its US distributor asked for documents to answer a marketplace safety review, the gaps appeared one after another.
- The FDA product listing still showed the 2024 ingredients. MoCRA requires the responsible person to update listings annually, and this one described a formula the brand no longer sold.
- The label ingredient list was not in the required order of predominance and used a trade name instead of the standard ingredient name for the botanical extract.
- The safety substantiation file was signed for the old formula. Nobody had assessed the new derivative at its use level, or the extract in a leave-on product used near the eyes.
The marketplace paused the listing until the documents were consistent. The distributor, which also sold other brands, asked for written assurance that the brand would not change formulas without telling it. Then a second retailer asked the same questions.
Putting it right
The brand commissioned a safety assessment of the new formula, which supported its safety with a precautionary statement to avoid the eye area. It corrected the label, had it reviewed, and updated its FDA product listing so the listing, the label and the formula finally matched. The work took about six weeks. During that time a product that made up a third of US revenue was mostly unavailable.
The lesson
Under MoCRA a formula change is never only a production decision. It touches three records that must agree: the product listing, the label, and the safety substantiation file. Build a simple change rule: no new formula ships until the safety file is re-signed, the label has been reviewed and the listing update is scheduled. Our article on when to bundle product listing and label review explains why the two are best done together. FDABridge's cosmetic product listing and cosmetics label review services are designed to be used at exactly this point.